| HOME >> MEDICINE >> TECHNOLOGY |
SWARTZ CREEK, Mich., May 5 /PRNewswire/ -- Diplomat Specialty Pharmacy announced today that their proprietary and exclusive Electronic Navigator (eNAV(TM)) patient care system is now live and being utilized to manage their multiple sclerosis patients. The company plans to use eNAV(TM) as a disease management tool for all disease states including HIV/AIDS, Hepatitis C, Oncology, Rheumatoid Arthritis, Dermatology, Crohn's Disease, and Chronic Kidney Disease.
"Our current best-in-class patient care process is now enhanced by our new electronic system," stated Phil Hagerman, President and CEO of Diplomat. "This new technology will validate our patient care algorithms and superior care models resulting in improved patient experiences. Using eNAV(TM) we can improve access to drug, patient adherence and healthy outcomes."
For the practicing physician this means that Diplomat has expanded its services to provide clinically relevant, pharmacist based interventions to improve patient care. Physicians can expect to receive electronically scheduled Medication Histories, Symptom Management Notifications, Contraindication Warnings, Depression Screening, Non-Adherence Alerts, and more.
The eNAV(TM) system will also broaden reporting and data capabilities for physicians and health plans.
Diplomat's new electronic patient care system provides "patient-centric" guidance through many steps of patient care including: Prior Authorizations, Complete Medication History, Disease Education, Disease Symptom Management, Relapse Education, Contraindication Assessment, Laboratory Education, Drug Education, Drug Side Effect Education, and much more.
"With help from expert opinion, several leading software companies, and
internal clinical support, we have designed a new course in modern
healthcare technology," stated H. Brent Hubble PharmD, Manager of Clinical
Program Development, and designer of the system. "eNAV(TM) is a streamline,
state-of- the art pa
'/>"/>
| SOURCE Diplomat Specialty Pharmacy Copyright©2008 PR Newswire. All rights reserved |